This is a compounded formulation dispensed as part of a supervised wellness protocol at Modern Wellness Clinic
ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
ZH and HX organized the methodology, investigation, and data collection
Overall, clearance of MHD is split ~50/50 between hepatic and renal clearance
Athletes and support personnel are urged to contact their National Anti-Doping Organisation (NADO) or IFMAs Anti-Doping Department if they have any doubts about the status of substances or methods
Diabetes Care 39 , 596602 (2016)